Epstein-Barr Virus & MS: Could Blocking Infection Prevent Multiple Sclerosis?

Over 95% of the world’s adult population carries the Epstein-Barr virus (EBV), yet most individuals remain unaware of its presence. While often asymptomatic, emerging research increasingly links EBV to a range of serious health conditions, most notably multiple sclerosis (MS).

For over 50 years, EBV has been recognized as a virus contributing to certain cancers and is classified as a group one carcinogen. More recently, a growing body of evidence suggests a significant role for EBV in the development of MS, a chronic autoimmune disease affecting the central nervous system. MS impacts millions globally, often diagnosed in young adulthood, and is characterized by unpredictable symptoms.

The underlying mechanism by which EBV might contribute to MS is now being investigated. In MS, the body’s immune system mistakenly attacks myelin, the protective sheath surrounding nerve fibers, disrupting communication between the brain and the body. This damage leads to a variety of symptoms, including difficulties with movement, vision, balance, and persistent fatigue.

Recent research, including a study involving over 10 million active-duty US military personnel between 1993 and 2013, has strengthened the association between EBV and MS. Researchers, led by Dr. Alberto Ascherio from the Harvard T.H. Chan School of Public Health, found that infection with EBV dramatically increased the odds of developing MS. This finding suggests that vaccines against the virus could potentially help prevent the disease.

A team of researchers explored how EBV infection may initiate MS. Their work, utilizing lab mice with human-like immune systems, revealed that following infection, B cells – immune cells responsible for antibody production and immune coordination – became unusually active and migrated into the brain. Within the brain, these B cells released signals attracting T cells, which identify and destroy infected or abnormal cells. This influx of immune cells triggered inflammation and early brain damage mirroring the processes believed to occur in the initial stages of MS.

Interestingly, when the researchers used a medication to remove the B cells, the number of T cells in the brain significantly decreased, along with a reduction in immune activation. This suggests that EBV may initiate MS by altering B cell behavior, causing them to enter the brain and drive inflammation, subsequently attracting T cells and intensifying the immune response.

Current MS treatments primarily focus on modulating the immune system to reduce inflammation and slow disease progression. Many of these treatments are immunosuppressants, which, while effective, can increase susceptibility to infections. Several effective MS therapies specifically target B cells using monoclonal antibodies, such as ocrelizumab, rituximab, and ofatumumab, reducing their numbers and potentially lowering the pool of EBV-infected cells.

The question arises: could preventing EBV infection altogether prevent the development of MS? While developing an EBV vaccine has proven challenging due to the virus’s ability to remain dormant within cells for life, researchers are actively exploring this possibility. It remains unclear whether preventing EBV infection would definitively reduce MS risk.

Researchers have also found unusually high numbers of EBV-targeting immune cells in the cerebrospinal fluid – the fluid surrounding the brain and spinal cord – of individuals with MS. Many of these were T cells primed to recognize the virus, indicating ongoing EBV activity within the central nervous system. This activity can trigger inflammation, allowing more immune cells to enter the brain and spinal cord, leading to the formation of lesions characteristic of MS.

Why doesn’t everyone infected with EBV develop MS? Other factors likely play a role, including genetic predisposition, sex, smoking, obesity, and vitamin D levels. EBV appears to be a significant piece of the puzzle, but it is unlikely to be the sole cause.

The link between EBV and MS is now a central focus of MS research, reshaping approaches to prevention and treatment. The field is shifting towards exploring strategies to stop EBV infection or target cells harboring the virus, potentially reducing an individual’s risk of developing MS or slowing its progression. This evolving understanding is driving the development of new therapies aimed at EBV-infected B cells and exploring vaccine strategies or immune-based treatments to interrupt the connection between the virus and MS.

If successful, these approaches could move MS care beyond symptom management towards prevention or earlier disease-modifying interventions.